Immunotherapy is a new genre of treatment for patients with advanced cancer. Initially approved for use in metastatic melanoma, immunotherapy has found a significant place in treating non-small cell lung cancer (NSCLC). Clinical trials using several combinations of immunotherapy are underway to help to determine the best treatment for specific patient groups. This article reviews approved uses of immunotherapy for NSCLC, immune-related toxicities, and explores the future direction of this treatment.
机构:
Saitama Med Univ, Int Med Ctr, Dept Resp Med, 1397-1 Yamane, Hidaka, Saitama 3501298, JapanSaitama Med Univ, Int Med Ctr, Dept Resp Med, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
机构:
Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo, Japan
Kitasato Univ, Sch Med, Dept Resp Med, Sagamihara, Kanagawa, JapanNatl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo, Japan
Shirasawa, Masayuki
Yoshida, Tatsuya
论文数: 0引用数: 0
h-index: 0
机构:
Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo, JapanNatl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo, Japan
Yoshida, Tatsuya
Ohe, Yuichiro
论文数: 0引用数: 0
h-index: 0
机构:
Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo, JapanNatl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo, Japan